Novo Nordisk

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. 

CEO
Maziar Mike Doustdar
CEOMaziar Mike Doustdar
Employees
76,302
Employees76,302
Headquarters
Bagsværd, Capital Region
HeadquartersBagsværd, Capital Region
Founded
1923
Founded1923
Employees
76,302
Employees76,302

NVO Key Statistics

Market cap
232.73B
Market cap232.73B
Price-Earnings ratio
14.55
Price-Earnings ratio14.55
Dividend yield
2.33%
Dividend yield2.33%
Average volume
9.79M
Average volume9.79M
High today
$53.03
High today$53.03
Low today
$51.60
Low today$51.60
Open price
$52.81
Open price$52.81
Volume
12.12M
Volume12.12M
52 Week high
$113.76
52 Week high$113.76
52 Week low
$45.05
52 Week low$45.05

NVO News

The Motley Fool 7h
If I Could Only Buy 2 Stocks in the Last Quarter of 2025, I'd Pick These

These two have been neglected by Wall Street too much. There are plenty of attractive stocks on the market. Some, though, have significantly underperformed the...

If I Could Only Buy 2 Stocks in the Last Quarter of 2025, I'd Pick These
TipRanks 21h
Novo Nordisk’s New Study on Haemophilia: What Investors Need to Know

Novo Nordisk ((NVO)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlo...

TipRanks 21h
Novo Nordisk’s New Study on Cagrilintide: A Potential Game-Changer in Weight Management

Novo Nordisk ((NVO)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock...

Analyst ratings

64%

of 33 ratings
Buy
63.6%
Hold
30.3%
Sell
6.1%

More NVO News

TipRanks 21h
Novo Nordisk’s New Weight Loss Study: A Potential Game-Changer in Obesity Treatment

Novo Nordisk ((NVO)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlo...

TipRanks 22h
Novo Nordisk’s New Study: A Potential Game-Changer for Chronic Kidney Disease Treatment?

Novo Nordisk ((NVO)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlo...

TipRanks 22h
Novo Nordisk’s Diabetes Study: A Potential Game-Changer?

Novo Nordisk ((NVO)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlo...

TipRanks 22h
Novo Nordisk’s Awiqli Study: A Real-world Insight into Diabetes Treatment

Novo Nordisk ((NVO)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlo...

TipRanks 23h
Novo Nordisk’s CagriSema Study: A New Horizon in Obesity Treatment

Novo Nordisk ((NVO)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlo...

TipRanks 23h
Novo Nordisk’s SELECT-LIFE Study: Long-term Insights on Semaglutide

Novo Nordisk ((NVO)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlo...

TipRanks 23h
Novo Nordisk’s Semaglutide Study: Real-World Insights on Cardiovascular and Obesity Outcomes

Novo Nordisk ((NVO)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlo...

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.